arrow
A

Armando Santoro

Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital
H指数:121
被引数:7.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial

作者更正:构象选择性PI3Kδ抑制剂roginolisib在晚期或转移性癌症患者中的研究,包括转移性眼黑色素瘤:首次人体临床试验

2026-11-130
OAAI
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial

在晚期或转移性癌症患者中具有构象选择性的PI3Kδ抑制剂roginolisib的临床试验:首次人体试验,包括转移性葡萄膜黑色素瘤

2026-10-090
OAAI
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) – A Trial in Progress

罗京诺利司与JAK抑制剂联合治疗对批准的JAK抑制剂无反应的真性红细胞增多症患者(研究HEMA-MED)——一项进行中的试验

2026-10-010
OAAI
Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study

Glofitamab与免疫化疗联合治疗复发/难治性B细胞非霍奇金淋巴瘤:1b期剂量递增研究

2026-09-050
OAAI
Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review

新型PET示踪剂以区分转移性睾丸生殖细胞肿瘤化疗后残留肿块的性质:一项系统综述

2026-07-020
OAAI
Development and Preliminary Validation of a Tool to Assess Barriers and Facilitators to Participation in Adjuvant Endocrine Therapy Switch Trials

开发并初步验证评估参与辅助内分泌治疗转换试验障碍与促进因素的工具

2026-06-170
OA
Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions

Cecchi, L.G.; Aliprandi, M.; De Vincenzo, F.; Perrino, M.; Cordua, N.; Borea, F.; Bertocchi, A.; Federico, A.; Marulli, G.; Santoro, A.; 等. 胸膜间皮瘤的围手术期治疗:现状与未来方向. Cancers 2025, 17, 3199. [Google Scholar] [CrossRef]

Cancers
IF4.4
2026-03-030
OAAI
Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience

苯达莫司汀联合吉西他滨和长春瑞滨作为复发或难治性外周T细胞淋巴瘤的挽救方案: 回顾性单中心经验

2026-01-210
PRE
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study

Alnuctamab,一种靶向B细胞成熟抗原的双价T细胞结合剂,用于复发或难治性多发性骨髓瘤患者:一项1期首次人体研究的成果

Leukemia
IF13.4
2026-01-070
OAAI
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

纳武利尤单抗联合 Brentuximab Vedotin 治疗复发/难治性弥漫性大B细胞淋巴瘤

2025-12-100
OAAI
[18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?

^{18}F-FDG PET/CT作为早期乳腺癌新辅助治疗中评估疗效的生物标志物:在新兴的增减量策略背景下,它能否成为变革性因素?

2025-12-010
OAAI
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer

RSC4All 作为一种机器学习列线图,用于预测 HR+/HER2- 淋巴结阴性早期乳腺癌的 RSClin™ 结果

2025-10-070
OAAI
Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis

与作为异基因干细胞移植前难治/复发霍奇金淋巴瘤挽救治疗的 brentuximab vedotin 相比,检查点抑制剂后复发的发生率降低:一项回顾性分析

2025-08-310
OAAI
Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy

基线止血生物标志物评估可识别化疗期间静脉血栓栓塞高风险的乳腺癌患者

2025-08-200
PRE
Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes

同种异体移植在嵌合抗原受体-T细胞失败并接触双特异性抗体后的可行性、安全性和生存结局

2025-07-220
OAAI